Chemomab Ltd.
🇮🇱Israel
Clinical Trials
7
Active:2
Completed:4
Trial Phases
2 Phases
Phase 1:4
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (57.1%)Phase 2
3 (42.9%)Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- ChemomAb Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT06210945
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Phase 1
Completed
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part OneDrug: Placebo - Study Part OneDrug: Anti-human CCL24 monoclonal antibody (CM-101) - Part TwoDrug: Placebo - Study Part Two
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- ChemomAb Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06044467
- Locations
- 🇮🇱
Hadassah University Hospital - Ein Kerem, Jerusalem, Israel
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Nonalcoholic Steatohepatitis (NASH)Primary Sclerosing Cholangitis (PSC)Systemic Sclerosis (SSc)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- ChemomAb Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT06037577
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: Anti-human CCL24 monoclonal antibody (CM-101)
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- ChemomAb Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06025851
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
CM-101 in NASH Patients - The SPLASH Study
Phase 2
Completed
- Conditions
- Nonalcoholic Steatohepatitis
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- ChemomAb Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT05824156
- Locations
- 🇮🇱
Soroka Medical Center - site 203, Be'er Sheva, Israel
🇮🇱Carmel Medical Center - site 207, Haifa, Israel
🇮🇱Rambam Medical Center - site 202, Haifa, Israel
- Prev
- 1
- 2
- Next
News
No news found